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ZiprasidonePharmacogenetic (PGx) predictors of response would improve outcomes in antipsychotic treatment. Based on
both biological rationale and prior evidence of an impact on Parkinson's disease, we conducted an association
study for 106 SNPs in the synaptic vesicle protein 2C (SV2C) gene using genetic and treatment response data
from the Clinical Trial of Antipsychotic Intervention Effectiveness (CATIE).We examined response to the atypical
antipsychotics for Caucasian subjects in the blinded phases, Phases 1A, 1B, and 2, of CATIE with sample sizes as
follows: olanzapine (N = 134), quetiapine (N = 124), risperidone (N = 134), and ziprasidone (N = 74). Re-
sponse was deﬁned as change in the Positive and Negative Syndrome Scale (PANSS) score using a mixed
model repeat measures approach. Subjects homozygous for the T allele of rs11960832 displayed signiﬁcantly
worse response to olanzapine treatment, the only ﬁnding with study-wide signiﬁcance (p = 2.94 × 10−5;
false discovery rate = 2.18 × 10−2). These subjects also displayed worse response to quetiapine with nominal
signiﬁcance (p = 4.56 × 10−2). While no other SNP achieved study-wide signiﬁcance, one SNP (rs10214163)
inﬂuencing Parkinson's disease displayed nominally signiﬁcant association with olanzapine and quetiapine re-
sponse, while the second such SNP (rs30196) showed a statistical trend toward correlating with olanzapine
and quetiapine response. Furthermore, both coding SNPs examined (rs31244 and rs2270927) displayed nomi-
nally signiﬁcant correlations with treatment response: one for olanzapine (rs227092), and one for quetiapine
(rs31244). The fact thatmultiple SNPs in SV2Cmay impact response to atypical antipsychotics suggests that fur-
ther evaluation of SNPs in this gene as PGx predictors of antipsychotic response is warranted.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license. 1. Introduction
Variation in response to antipsychotic treatment complicates the
treatment of patients with schizophrenia, and pharmacogenetic (PGx)
predictors of efﬁcacy for antipsychotics have proven challenging to
ﬁnd. Several studies have been published on PGx response to antipsy-
chotics, most of which have focused on Genome Wide Association
Study (GWAS) approaches using an additive genetic model (Volpi et
al., 2009; Adkins et al., 2011; McClay et al., 2011; Aberg et al., 2012;
Fijal et al., 2012; Liu et al., 2012). Though often overlooked, genetic var-
iants might just as well impact treatment response via other modes of
inheritance (as tested by dominant and recessive genetic models)
(Lavedan et al., 2009; Need et al., 2009; Fijal et al., 2012).
Recently, the synaptic vesicle protein 2C (SV2C) gene was identiﬁed
as a potential pharmacogenetic (PGx) modulator of nicotine's: +1 859 663 2984.
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.V.Open access under CC BY-NC-SA licprotective effect on Parkinson's disease incidence (Hill-Burns et al.,
2012). Following a genome-wide scan for interaction with smoking
and Parkinson's disease, the authors identiﬁed eighteen single nucleo-
tide polymorphisms (SNPs) in the promoter region and early 5′ portion
of the gene that moderated the impact of smoking on Parkinson's sus-
ceptibility. Interestingly, rather than experiencing a protective effect
from nicotine consumption, subjects homozygous for the minor alleles
of rs10214163 and rs30196 experienced an increased incidence of
Parkinson's disease.
The SV2C protein has a number of characteristics that may have
relevance to the pathophysiology and pharmacological treatment of
affective disorders and psychosis. SV2C is found on the surface of syn-
aptic vesicles, and it has been hypothesized that SV2C plays a role in
synaptic function (Dardou et al., 2013). In mice, SV2C has restricted
distribution in the brain, being found in speciﬁc regions of the stria-
tum, substantia nigra, neostriatum, and pallidum (Dardou et al.,
2011). Expression of SV2C is inversely linked to tyrosine hydroxylase
expression, with SV2C knockout mice exhibiting large increases in
production of tyrosine hydroxylase mRNA (Dardou et al., 2013). As
tyrosine hydroxylase is the rate-limiting enzymatic step in the pro-
duction of dopamine and norepinephrine, SV2C may play a critical
role in catecholamine-mediated activities of the basal ganglia
(Dardou et al., 2013). Consistently, decreased SV2C expressionense. 
Table 1
Sample characteristics.
Treatment Sample
Size
Mean
Baseline(SD)a
Mean age
(SD)b
# of
Femalesb
# of
Malesb
Olanzapine 134 73.5 (18.8) 40.5 (11.6) 34 100
Quetiapine 124 73.5 (18.0) 40.5 (11.2) 29 95
Risperidone 134 77.5 (17.2) 42.2 (11.4) 29 105
Ziprasidone 74 71.3 (16.2) 40.1 (11.1) 21 53
a Baseline PANSS was a signiﬁcant contributor to drug response and therefore was
incorporated into the mixedmodel that provided the response variable used for the ge-
netic analysis.
b Both sex and age were considered for inclusion in the response model; however as
they did not signiﬁcantly contribute to response they were not included in the ﬁnal
mixed model.
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dure, abolishing the preference for cocaine-associated locations
(Dardou et al., 2013). Additionally, SV2C appears to preferentially
co-localize with Gamma Amino Butyric Acid (GABA) vesicles but
not glutamate vesicles (Gronborg et al., 2010). Outside the brain,
SV2C is highly expressed in the pancreas, especially in islet cells. It
has been linked to glucose-mediated but not Ca++-mediated insulin
release (Iezzi et al., 2005).
SV2C has many attributes that make it an interesting candidate
PGx gene for antipsychotic response. While the exact mechanism of
action for SV2C with regard to vesicle transport of hormones and neu-
rotransmitters remains unclear, its involvement with both GABA and
insulin transporters may have implications in the etiology of schizo-
phrenia and its treatment. It is expressed in dopaminergic neurons lo-
cated in brain areas associated with the pathology of psychosis
(Dardou et al., 2013). The entire group of synaptic vesicle family 2
proteins (SV2A, SV2B, and SV2C) provides key components of neuro-
transmitter vesicles (Gronborg et al., 2010). These proteins interact
with many components of the vesicle structure. SV2C appears to be
associated preferentially with GABA vesicles and not associated with
glutamate vesicles, which instead show enrichment of SV2B protein
levels (Gronborg et al., 2010). Several laboratories have shown that
down-regulation of mRNAs encoding glutamic acid decarboxylase
67 and reelin decreases the cognate proteins coexpressed in prefron-
tal cortex GABAergic neurons of post-mortem schizophrenic and bi-
polar brains (Guidotti et al., 2005). GABAergic neurons release
reelin that can interact with integrin receptors on cortical pyramidal
neurons and regulate mRNA translation. The hypoplasticity of the
prefrontal cortex in schizophrenia and bipolar disorder may be asso-
ciated with such downregulation and may play a role in negative
symptomatology.
In the current study, we explored the impact of SNPs in the SV2C
gene on response to atypical antipsychotics in Caucasian subjects in
the Clinical Antipsychotic Trials of Intervention Effectiveness
(CATIE) study of antipsychotic response in schizophrenia. This analy-
sis evaluated the three commonmodels of genetic variation (additive,
dominant, and recessive) using the mixed model approach developed
previously as a measure of pharmacological response (van den Oord
et al., 2009; Liu et al., 2012). We report the top results for these anal-
yses and discuss the implications for further evaluation of genetic
variation in the SV2C gene as potential PGx markers for antipsychotic
response.
2. Materials and methods
2.1. Patients
The patient population and the CATIE data used are described in
detail elsewhere (Stroup et al., 2003; Lieberman et al., 2005;
Sullivan et al., 2008; Liu et al., 2012). Brieﬂy, this study was limited
to self-described Caucasian subjects, diagnosed with schizophrenia
and participating in the CATIE trial. All subjects in this study provided
informed consent for genetic testing and participated in at least one
of the randomized phases of the study, Phases 1A, 1B, and 2
(Lieberman et al., 2005). For each drug, Table 1 presents total number
of patients treated, mean and standard deviation for baseline PANSS
score and age, and distribution between the sexes. The Center for Col-
laborative Genomic Studies on Mental Disorders (CCGSMD) provided
the genotypes and phenotypes, including drug response data.
2.2. Measures of response and drugs used
As described previously, we used data from all time points available
from Phases 1, 1A, and 2 in CATIE from Caucasian subjects treated with
atypical antipsychotics to develop a treatment response variable. The
sample sizes were as follows: olanzapine, 134; perphenazine, 75;quetiapine, 124; risperidone, 134; and ziprasidone, 74. We implemented
the mixed model repeated measures (MMRM) approach developed by
Van den Oord et al. (van den Oord et al., 2009; McClay et al., 2011) as a
method of modeling antipsychotic response. This model predicted an
overall response as deﬁned as change in Total Score on Positive and Neg-
ative SyndromeScale (PANSS-T). PANSS-T provided a continuous variable
for use in genetic analysis.
2.3. Statistical methods
For each atypical antipsychotic arm, we conducted genetic associ-
ation analysis in SVS version 7.3.1 software package (Golden Helix
Inc. Bozeman, MT) using the additive, dominant, and recessive
models with change in PANSS-T as the dependent variable. The ge-
netic association analysis tested the null hypothesis that subjects
with varying combinations of minor alleles did not display a differ-
ences in mean PANSS-T for a given drug treatment.
When choosing a p-value threshold to report, one must strike a
balance between concerns for false positive and disregarding true sig-
nals due to sample size issues. Because this study was a candidate
gene study with several lines of evidence suggesting that the SV2C
gene might have a PGx impact on antipsychotic drug response, we
have reported all nominally signiﬁcant results. We evaluated the im-
pact of tobacco use and alcohol consumption status for all nominally
signiﬁcant ﬁndings (using CCGSMD-provided status at study enroll-
ment) by analysis of variance (ANOVA).
To mitigate false positives resulting from the small sample sizes
found for some rarer groups comprising homozygous individuals, only
those SNPs with homozygosity for the minor allele at a frequency
≥0.03 in a given drug arm were used. For SNPs for which there were
no cases of homozygosity for theminor alleles, we tested only the dom-
inant model. We analyzed a total of 106 SNPs beginning with
rs11960832 in the promoter region and concluding with rs2913257,
the 3′ most SNP lying within the transcribed region that was included
in the CCGSMD-provided data. Excluding the rare andmissing genotype
groups resulted in a total of 742 individual tests needed to evaluate the
four atypical antipsychotics using the three genetic models. The
Benjamini method for False Discovery Rate (FDR) was used to correct
for multiple comparisons (Benjamini et al., 2001).
To evaluate if multiple ﬁndings for a given drug were due to corre-
lation between the SNPs, we determined the pairwise r2 values for all
nominally signiﬁcant ﬁndings. These linkage disequilibrium (LD)
values were calculated along with a graphical representation of the
results using Haploview software (version 4.2) (Barrett et al., 2005).
3. Results
3.1. SV2C SNP association results for response to atypical antipsychotics
Table 2 lists results (p b 0.05) from the SNP association analysis
for PGx impact on the atypical antipsychotics in the CATIE trial. Of
Table 2
Nominally signiﬁcant association results for atypical antipsychotics in the CATIE trial.
Rs# Chr Base pair Minor allele p-Valuea FDRb Responsec Genetic modeld
Olanzapine
11960832e 5 75550742 T 2.94E−05 2.18E-02 Worse Recessive
3.39E−02 9.96E-01 Worse Additive
4580760 5 75476111 A 2.47E−03 9.16E-01 Better Additive
3.35E−02 9.96E-01 Better Dominant
10214163f 5 75330166 C 1.40E−02 9.96E-01 Worse Additive
4.00E−02 9.96E-01 Worse Dominant
1995381 5 75606414 G 2.01E−02 9.96E-01 Worse Dominant
2270927g 5 75627466 G 2.47E−02 9.96E-01 Worse Dominant
6874435 5 75610611 G 3.22E−02 9.96E-01 Worse Dominant
2112865 5 75465359 G 4.18E−02 9.96E-01 Better Dominant
Quetiapine
10214163f 5 75330166 C 4.62E−03 9.96E-01 Better Dominant
5.90E−03 9.96E-01 Better Additive
2134227 5 75436223 C 7.77E−03 9.96E-01 Better Dominant
8.32E−03 9.96E-01 Better Additive
31244g 5 75630499 A 2.35E−02 9.96E-01 Worse Dominant
11960832e 5 75550742 T 4.56E−02 9.96E-01 Worse Recessive
Risperidone
7732173 5 75513419 A 1.76E−02 9.96E-01 Worse Recessive
10514062 5 75513972 T 1.76E−02 9.96E-01 Worse Recessive
2358531 5 75515542 G 1.76E−02 9.96E-01 Worse Recessive
1995380 5 75548413 C 2.35E−02 9.96E-01 Better Dominant
6882321 5 75599586 C 3.82E−02 9.96E-01 Better Dominant
Ziprasidone
12522597 5 75467455 A 1.01E−02 9.96E-01 Better Dominant
12655684 5 75528458 T 3.79E−02 9.96E-01 Better Dominant
4.95E−02 9.96E-01 Better Additive
a The trend correlation p-value (see Material and methods Section 2.3) for a given drug; SNPs are listed by increasing p-value. Additional nominally signiﬁcant association(s) of a
SNP using a different genetic model is listed immediately following the most signiﬁcant result.
b False Discovery Rate (see Material and methods Section 2.3).
c Better response is deﬁned as a greater decrease in PANSS-T than the mean for a given arm. Worse response is deﬁned as a smaller decrease (including increases) in PANSS-T
than the mean for a given arm.
d Describes the type of genetic model used for the association analysis.
e SNP remained signiﬁcant after FDR correction in the olanzapine arm and also impacted response in the quetiapine arm.
f Candidate SNP for nicotine impact on Parkinson's risk (Hill-Burns et al., 2012).
g SNP leads to amino acid coding change.
23T.L. Ramsey et al. / Schizophrenia Research 149 (2013) 21–25the 106 SNPs tested, each in three genetic models, a total of only 16
different SNPs produced nominally signiﬁcant results.
Of these, only the recessive model for rs11960832 and olanzapine
response survived correction for multiple-testing. Subjects homozy-
gous for the minor allele of this SNP displayed signiﬁcantly worse re-
sponse when treated with olanzapine compared to subjects with at
least one copy of the major allele. Interestingly, homozygosity for
this same minor allele correlated with poor response in subjects
treated with quetiapine as well. In addition, the additive model for
this SNP was nominally signiﬁcant for olanzapine response.
One of the two SNPs previously shown to inﬂuence the impact of
nicotine on Parkinson's also appears in Table 2 (Hill-Burns et al.,
2012). In the present study, rs10214163 was the third most signiﬁcant
SNP for olanzapine response and themost signiﬁcant SNP for quetiapine
response. The presence of the minor (C) allele of this SNP correlated
with poorer response to olanzapine, but better response to quetiapine.
While the other SNP implicated in nicotine and Parkinson's, rs30196,
does not appear in Table 2, it barelymissed the threshold in the additive
model of olanzapine response with a p-value of 0.057.
It is also worth noting that both of the SV2C coding variants included
in the genotypes provided by CCGSMD (rs31244 and rs2270927) appear
in Table 2. Using a dominantmodel, theminor allele of rs31244 correlat-
edwith poorer response to quetiapine, and theminor allele of rs2270927
correlated with poorer response to olanzapine. Additionally, the domi-
nant model for rs31244 displayed a trend for poorer response to
olanzapine (p-value = 0.12), and the dominant model for rs2270927
displayed a trend for poorer response to quetiapine (p-value = 0.18).
Neither SNP correlated with response for the other two drugs, risperi-
done and ziprasidone (p-values N 0.9).Ziprasidone produced the fewest nominally signiﬁcant results.
One possible explanation for this observation is the limited sample
size available for ziprasidone. Ziprasidone was added to the CATIE
protocol after initiation of the study. Therefore, ziprasidone was un-
derrepresented in Phase 1A and completely absent in Phase 1B
resulting in a lower total number of subjects treated for this drug.
Given the prior evidence of a gene-by-environment interaction
between the SV2C gene and nicotine (Hill-Burns et al., 2012), it was
of interest to determine if tobacco or alcohol consumption impacted
the results in Table 2. Accordingly, we performed ANOVA for all the
SNPs and corresponding genetic models shown in Table 2 to test for
a gene-by-environment interaction with these environmental factors.
Within rounding error for p values, neither variable individually nor
combined improved the model ﬁt for any of the ﬁndings listed in
Table 2.
3.2. Linkage disequilibrium (LD) results for signiﬁcant SNPs
Fig. 1 summarizes the LD relationships between the various SNPs
listed in Table 2. For the most part the SNPs appear to capture genet-
ically independent loci, with some interesting exceptions.
In the case of risperidone, the top three SNPs are highly correlated as
can be seen by the r2 values which exceed 0.95 for between pairwise
comparisons for rs773217, rs10514062, and rs2358531. Thus it is not
surprising that the p-values and the best genetic model (recessive) ﬁt
for risperidone response are the same for these three SNPs.
Another area of LD for signiﬁcant SNPS includes the two coding vari-
ants. Three SNPs, rs1995381, rs687443, and rs2270927 (the latter being a
coding variant) correlate with olanzapine response. Here again the
Fig. 1. Linkage disequilibrium plot of signiﬁcant SNPs. The SNPs in Table 2 were used as input for Haploview to calculate linkage disequilibrium parameters for the 16 unique SNPs in
Table 2 (see Materials and methods Section 2.3). The number inside the diamonds represents the r2 value for the given 2-SNP pair. The capital letter(s) following each rs number
identiﬁes the drug(s) for which ﬁndings are listed in Table 2 as follows: O = olanzapine; Q = quetiapine; R = risperidone; and Z = ziprasidone.
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(dominant) is the same for olanzapine response for each SNP. The two
coding variants, rs2270927 and rs31244 are also in LD with one other.
While only rs31244 correlates with quetiapine response at the
p ≤ 0.05 level, the minor allele does correlate with poorer response to
quetiapine, with a dominant genetic model similar to what is seen for
rs2270927 and olanzapine response.4. Discussion
Out of a total of 106 markers that we examined using three genet-
ic models in four drug arms from CATIE, genotypes of only one SNP,
rs11960832 as related to olanzapine response, survived correction
for multiple testing. The same SNP also displayed a nominally signif-
icant correlation to quetiapine response.
Consistently, some of our other ﬁndings suggest that variation in
the SV2C gene may selectively impact response to the benzodiazepine
derivatives, olanzapine and quetiapine, relative to risperidone, and
ziprasidone. Genotypes for one of the two SNPs previously associated
with nicotine's impact on Parkinson's disease risk, rs10214163
(Hill-Burns et al., 2012), correlated with response to olanzapine and
quetiapine, but not to risperidone and ziprasidone. Furthermore both
of the coding variants tested may affect response to olanzapine and/or
quetiapine but not to the other two atypical antipsychotics. It is unclear
why variation in the SV2C gene may preferentially affect response to
olanzapine and quetiapine, but it could potentially relate to the differ-
ential receptor binding afﬁnities for the benzodiazepine derivatives.
SV2C gene variation appears to modulate the protective effect of
nicotine on Parkinson's disease risk (Hill-Burns et al., 2012). Given
that nicotine enhances dopamine release in the brain and that SV2Cis densely expressed in the substantia nigra, Hill-Burns et al. (2012)
hypothesized that SV2C expression levels may alter neurotransmis-
sion in these dopaminergic neurons. The ties to both dopamine and
GABA, combined with high expression in areas associated with the
pathology of schizophrenia, provide intriguing biological rationale
for the involvement of SV2C in the mechanism of action of antipsy-
chotic medications. Moreover, SV2C has been linked to glucose-
mediated insulin release in the pancreas (Iezzi et al., 2005). Since
the antipsychotics can disrupt this process, the glucose–insulin con-
nection may be worthy of further investigation.
In summary, several lines of evidence suggest that variation in the
SV2C gene may differentially inﬂuence response to antipsychotics. Ge-
notypes for ﬁve of the 106 SNPs evaluated, including the four SNPs
with prior evidence of a role in protein structure or interaction with
the neuroactive compound nicotine, correlated with olanzapine and
quetiapine response. Variation in several other SNPs may impact re-
sponse to risperidone or ziprasidone. Thus, further investigation of the
role of SV2C gene variation in antipsychotic treatment response seems
justiﬁed.
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